Biohaven is a pharmaceutical company with an ataxia research programme. They carried out a clinical trial testing Troriluzole in a number of SCAs. Results of this 48 week trial showed that there was a treatment benefit to people with Spinocerebellar ataxia type 3 (SCA3).
Following these positive results for SCA3, Biohaven announced that they have submitted a New Drug Application (NDA) to the regulators in America (the FDA) for the treatment of SCA3.
Read more in their press release here.